Sanofi American Depositary Receipt (SNY)
Sanofi: Is Dupixent Too Successful?
Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help address the issue.
Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal
Sanofi (SNY) remains a Buy, driven by Dupixent's robust growth and expanding indications, notably with the recent COPD launch. SNY's Q3 saw total revenues rise 7% CER to €12.43 billion, with Dupixent contributing over €4 billion for the first time. Beyond Dupixent, SNY is diversifying with specialty launches like Altuviiio in hemophilia and Beyfortus in RSV, plus a strong pipeline and share buybacks.
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance
Pharmaceutical launches and increased demand for its blockbuster Dupixent drug lifted net sales by 7% in the third quarter.
SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study
Sanofi's efdoralprin alfa meets all key endpoints in a global phase II study, showing potential as a first restorative recombinant therapy for AATD.
Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade)
Sanofi is repositioned as a pure pharma play. Following an earnings reset, we see support in ongoing buybacks and higher sales guidance. Q2 results showed strong Dupixent growth, and 2026 readouts offer key positive catalysts. Valuation discount offers upside. Indeed, Sanofi trades at a 19% discount to EU pharma peers.
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.
Sanofi's Eczema Drug Candidate Hits Main Goals in Late-Stage Trial
Amlitelimab showed efficacy in skin clearance and disease severity compared to placebo in a phase 3 study with adolescent and adults with atopic dermatitis.
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease
Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.
Sanofi: Playing To Win
Sanofi's strategic pivot to immunology and rare diseases, plus AI-driven R&D, targets higher margins and sustainable long-term growth. Blockbuster drugs like Dupixent, Altuviiio, and Beyfortus, alongside a robust late-stage pipeline, underpin future revenue potential. Risks include heavy Dupixent reliance, looming patent expirations, US policy uncertainty, and ongoing legal disputes with Regeneron.
